4-Amino-N-methyl-benzamide/4-Amino-N-methylbenzamide/4-Amino-benzoesaeure-methylamid/Benzamide, 4-amino-N-methyl-/N-methyl-p-aminobenzamide/4-(methylcarbamoyl)aniline/4-Amino-N-methyl-benzamid/4-Aminobenzoylmethylamide/(4-aminophenyl)-N-methylcarboxamide/4-amino-benzoic acid methylamide
364.1±25.0 °C at 760 mmHg
HS Code Reference
Personal Projective Equipment
For Reference Standard and R&D, Not for Human Use Directly.
provides coniferyl ferulate(CAS#:6274-22-2) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
Whole-genome sequencing data allow detection of copy number variation (CNV) at high resolution. However, estimation based on read coverage along the genome suffers from bias due to GC content and other factors. Here, we develop an algorithm called BIC-seq2 that combines normalization of the data at the nucleotide level and Bayesian information criterion-based segmentation to detect both somatic and germline CNVs accurately. Analysis of simulation data showed that this method outperforms existing methods. We apply this algorithm to low coverage whole-genome sequencing data from peripheral blood of nearly a thousand patients across eleven cancer types in The Cancer Genome Atlas (TCGA) to identify cancer-predisposing CNV regions. We confirm known regions and discover new ones including those covering KMT2C, GOLPH3, ERBB2 and PLAG1. Analysis of colorectal cancer genomes in particular reveals novel recurrent CNVs including deletions at two chromatin-remodeling genes RERE and NPM2. This method will be useful to many researchers interested in profiling CNVs from whole-genome sequencing data.
Copy number analysis of whole-genome data using BIC-seq2 and its application to detection of cancer susceptibility variants
Ruibin Xi,corresponding author1 Semin Lee,2 Yuchao Xia,1,3 Tae-Min Kim,4 and Peter J Parkcorresponding author2
2016 Jul 27
Aging population presents a major challenge for many countries in the world and has made the development of efficient means for healthspan extension a priority task for researchers and clinicians worldwide. Anti-aging properties including antioxidant, anti-inflammatory, anti-tumor, and cardioprotective activities have been reported for various phytobioactive compounds (PBCs) including resveratrol, quercetin, curcumin, catechin, etc. However, the therapeutic potential of orally administered PBCs is limited by their poor stability, bioavailability, and solubility in the gastrointestinal tract. Recently, innovative nanotechnology-based approaches have been developed to improve the bioactivity of PBCs and enhance their potential in preventing and/or treating age-associated disorders, primarily those caused by aging-related chronic inflammation. PBC-loaded nanoparticles designed for oral administration provide many benefits over conventional formulations, including enhanced stability and solubility, prolonged half-life, improved epithelium permeability and bioavailability, enhanced tissue targeting, and minimized side effects. The present review summarizes recent advances in this rapidly developing research area.
Aging, Age-associated disorder, Phytobioactive compound, Bioavailability, Nanoparticle, Antioxidant, Anti-inflammatory activity
Nanodelivery of phytobioactive compounds for treating aging-associated disorders
Oleh Lushchak,corresponding author1 Olha Strilbytska,1 Alexander Koliada,2 Alina Zayachkivska,1 Nadia Burdyliuk,1 Ihor Yurkevych,1 Kenneth B. Storey,3 and Alexander Vaisermancorresponding author2
Mitral valve prolapse.
1981 May 2;